Your browser doesn't support javascript.
loading
Cancer Metastasis: The Role of the Extracellular Matrix and the Heparan Sulfate Proteoglycan Perlecan.
Elgundi, Zehra; Papanicolaou, Michael; Major, Gretel; Cox, Thomas R; Melrose, James; Whitelock, John M; Farrugia, Brooke L.
Afiliação
  • Elgundi Z; Graduate School of Biomedical Engineering, UNSW Sydney, Sydney, NSW, Australia.
  • Papanicolaou M; The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, UNSW Sydney, Darlinghurst, NSW, Australia.
  • Major G; School of Life Sciences, University of Technology Sydney, Sydney, NSW, Australia.
  • Cox TR; The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, UNSW Sydney, Darlinghurst, NSW, Australia.
  • Melrose J; The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, UNSW Sydney, Darlinghurst, NSW, Australia.
  • Whitelock JM; St Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, NSW, Australia.
  • Farrugia BL; Graduate School of Biomedical Engineering, UNSW Sydney, Sydney, NSW, Australia.
Front Oncol ; 9: 1482, 2019.
Article em En | MEDLINE | ID: mdl-32010611
ABSTRACT
Cancer metastasis is the dissemination of tumor cells to new sites, resulting in the formation of secondary tumors. This process is complex and is spatially and temporally regulated by intrinsic and extrinsic factors. One important extrinsic factor is the extracellular matrix, the non-cellular component of tissues. Heparan sulfate proteoglycans (HSPGs) are constituents of the extracellular matrix, and through their heparan sulfate chains and protein core, modulate multiple events that occur during the metastatic cascade. This review will provide an overview of the role of the extracellular matrix in the events that occur during cancer metastasis, primarily focusing on perlecan. Perlecan, a basement membrane HSPG is a key component of the vascular extracellular matrix and is commonly associated with events that occur during the metastatic cascade. Its contradictory role in these events will be discussed and we will highlight the recent advances in cancer therapies that target HSPGs and their modifying enzymes.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Oncol Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Austrália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Oncol Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Austrália